DOV 51892Alternative Names: DOV-51892
Latest Information Update: 17 Nov 2007
At a glance
- Originator DOV Pharmaceutical
- Class Anxiolytics
- Mechanism of Action GABA A receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 11 Feb 2004 Preclinical trials in Anxiety disorders in USA (unspecified route)